STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety. Umecrine Cognition is developing a new cl ...

STOCKHOLM, SWEDEN – May 7, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will attend the EASL Congress 2025 in Amsterdam, May 7–10, to present validation and implementation data for the newly developed clinical scale for Primary Biliary Cholangitis, PBC.Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's drug candidate golexanolone is currently being evaluated in ...

STOCKHOLM, SWEDEN – May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J. Fox Foundation (MJFF) amounting to USD 420,000. The grant will finance preclinical studies to evaluate the potential treatment effect of golexanolone in Parkinson’s disease. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms. The company's drug candidate golexanolone has demonst ...

STOCKHOLM – 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. “Developmental intensity levels remain high in our portfolio companies, many of which have progressed their positions during the first quarter of the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company AnaCardio secured SEK 205 million in a series A ext ...